Illumina, Inc.
ILMNDiagnostics & Research
$290.06+0.44%As of Oct 29vs prior close
- Market cap
- $43.8B
- P/E (TTM)
- 53.7×
- P/E (FY1)
- 53.0×
- From 52W high
- −1.24%
- EPS (LTM)
- $5.81
- Revenue (LTM)
- $4.5B
- Net margin
- 18.36%
- Dividend yield
- 0.00%
Nomior Score
74
Steady ProfileTop 6% of the scored universe
Growth51
Quality77
Value42
Momentum98
Resilience55
Growth
+6.82%revenue a year over 9 fiscal years
FY16 $2.4BLTM $4.5B
Connections
Revenue to profitQ3 FY26
19% of revenue became net profit, up 6 pts on a year.
Latest resultsthird quarter of fiscal year 2026
- Revenue
- $1.13 billion
- Diluted EPS
- $1.43
- Revenue outlook
- $4.64-$4.66 billion
- EPS outlook
- $5.40-$5.45
Revenue and profit grew in the quarter, driven by healthy clinical demand and robust NovaSeq X placements that pushed results above the company's guidance. Excluding tariff refunds, operating profitability was strong and cash generation improved. Management raised its full-year revenue and earnings guidance.
Who owns it
2funds, 1 tracked portfolio